Core Viewpoint - Neurothera Labs Inc. has received a patent from the Israel Patent Office for its proprietary combination of opioids and N-acylethanolamines, aimed at enhancing the therapeutic effects of opioids while reducing side effects [1][2]. Group 1: Patent and Technology - The newly granted patent in Israel complements existing patents in Europe, Japan, Australia, and Canada, thereby strengthening the global intellectual property protection for Neurothera's opioid-based platform [2]. - The patented technology utilizes N-acylethanolamines, such as palmitoylethanolamide (PEA), to enhance opioid analgesia through synergistic mechanisms, allowing for effective pain relief at lower doses [2]. Group 2: Research and Efficacy - A pre-clinical study evaluated the nociceptive effect of PEA combined with opiates like oxycodone, demonstrating that the proprietary drug combination could reduce adverse psychoactive effects associated with oxycodone [3][4]. - The study found that PEA not only mitigated some negative side effects of oxycodone but also prolonged its analgesic effects across all doses tested [4]. Group 3: Market Context - The global market for oxycodone drugs is projected to be valued between $5.5 billion and $5.7 billion in 2024, highlighting the significant sales potential despite the risks associated with opioid use [5]. - The "opioid-sparing" effect of Neurothera's combination may lead to reduced opioid dosages, potentially addressing issues like addiction and respiratory depression [6]. Group 4: Company Perspective - The CEO of Neurothera emphasized the importance of the patent grant, which validates the advantages of their proprietary combination in providing effective pain relief while ensuring patient safety [7].